current
expans
novel
human
respiratori
coronaviru
known
sever
acut
respiratori
syndrom
coronaviru
coronaviru
diseas
novel
coronaviru
stress
need
therapeut
altern
allevi
stop
new
epidem
previou
epidem
infect
highmorbid
human
coronavirus
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
prompt
character
compound
could
potenti
activ
current
emerg
novel
coronaviru
promis
compound
remdesivir
nucleotid
analog
prodrug
current
clinic
trial
treat
ebola
viru
infect
remdesivir
inhibit
replic
sarscov
merscov
tissu
cultur
display
efficaci
nonhuman
anim
model
addit
combin
human
immunodefici
viru
type
proteas
inhibitor
lopinavirritonavir
interferon
beta
shown
effect
patient
infect
sarscov
also
improv
clinic
paramet
marmoset
mice
infect
merscov
remark
therapeut
efficaci
remdesivir
appear
superior
merscov
transgen
human
mous
model
rel
high
mortal
rate
associ
three
novel
human
coronaviru
infect
sarscov
merscov
suggest
proinflammatori
respons
might
play
role
pathogenesi
remain
unknown
whether
gener
inflammatori
state
target
therapeut
target
coronaviru
alon
might
abl
revers
highli
pathogen
infect
minireview
aim
provid
summari
therapeut
compound
shown
potenti
fight
infect
mainli
produc
respiratori
tract
infect
observ
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
sequenc
phylogenet
analys
shown
novel
strain
close
relat
group
human
sarslik
coronavirus
bat
sarsrel
coronavirus
origin
remain
unclear
unknown
first
transmit
human
high
preval
sarsrel
coronavirus
bat
suggest
bat
coronaviru
might
jump
civet
mammal
human
start
former
sar
epidem
initi
confirm
case
associ
huanan
seafood
liveanim
market
howev
anim
sourc
identifi
date
spillov
event
may
continu
occur
although
bat
might
sourc
critic
identifi
intermedi
speci
stop
current
spread
prevent
futur
human
sarsrel
coronaviru
epidem
key
issu
whether
current
epidem
similar
sar
outbreak
whether
show
differ
featur
epidemiolog
clinic
characterist
indic
new
outbreak
differ
outbreak
display
higher
transmiss
lower
mortal
shown
effici
intrafamili
spread
asymptomat
period
infect
oscil
day
individu
probabl
transmit
viru
without
develop
diseas
symptom
remain
elucid
whether
viru
replic
readili
upper
airway
sarscov
merscov
whether
similar
human
coronavirus
hcov
caus
cold
pneumonia
necessari
identifi
molecular
determin
mediat
transmiss
anim
human
human
human
note
novel
strain
nucleotid
sequenc
extern
ectodomain
spike
protein
receptorbind
domain
differ
sarscov
individu
bat
coronaviru
spike
gene
introduc
sarscov
infecti
clone
sarscovbatcov
spike
virus
could
bind
human
bat
civet
angiotensin
convert
enzym
cellular
receptor
understand
interact
novel
spike
protein
host
receptor
might
reveal
viru
overcam
speci
barrier
anim
human
discuss
inform
might
promot
design
effect
antivir
predict
new
zoonot
coronaviru
jump
across
speci
understand
rate
viru
spread
among
peopl
crucial
determin
whether
mutat
improv
bind
human
receptor
infect
rna
viru
intrins
genet
variabl
result
high
mutat
rate
moreov
coronavirus
largest
genom
kb
among
rna
virus
howev
part
sequenc
encod
proofread
exonucleas
increas
replic
fidel
suggest
adapt
sequenc
might
make
effici
transmit
person
person
might
also
increas
virul
howev
mechan
could
lead
genet
bottleneck
known
muller
ratchet
could
significantli
decreas
viral
fit
muller
ratchet
predict
mutat
rate
high
signific
proport
mutat
deleteri
type
irrevers
ratchet
mechan
gradual
reduc
mean
fit
small
popul
asexu
organ
genet
bottleneck
rna
virus
often
occur
respiratori
droplet
transmiss
expect
becom
less
virul
humantohuman
transmiss
public
health
perspect
urgent
need
develop
effect
vaccin
antivir
therapeut
stop
epidem
moreov
social
econom
issu
gener
epidem
also
call
rapid
intervent
review
focus
potenti
repurpos
preexist
compound
might
provid
new
opportun
treat
peopl
infect
previou
work
sarscov
merscov
provid
opportun
acceler
identif
meaning
therapi
fight
novel
epidem
nevertheless
must
awar
current
compound
target
sarscov
merscov
move
beyond
phase
trial
promis
antivir
fight
remdesivir
remdesivir
adenosin
nucleotid
analogu
prodrug
broadspectrum
antivir
activ
filovirus
paramyxovirus
pneumovirus
pathogen
coronavirus
like
sarscov
merscov
pharmacokinet
studi
complet
clinic
trial
ongo
test
remdesivir
efficaci
treat
ebola
viru
previou
studi
indic
nucleotid
analogu
gener
show
low
efficaci
coronavirus
due
presenc
viru
exonucleas
proofread
enzym
nevertheless
remdesivir
found
effect
sarscov
merscov
bat
cov
strain
tissu
cultur
remdesivir
display
halfmaxim
effect
concentr
ec
sarscov
merscov
note
tissu
cultur
studi
shown
remdesivir
also
activ
submicromolar
ec
rang
number
highli
diverg
coronavirus
includ
endem
human
cov
thu
remdesivir
broadspectrum
anticov
activ
mous
model
sarscov
pathogenesi
prophylact
earli
therapeut
administr
remdesivir
significantli
reduc
lung
viral
load
viral
titer
reduc
order
magnitud
day
postinfect
remdesivir
improv
clinic
sign
diseas
respiratori
function
compar
untreat
control
anim
compar
result
obtain
merscov
prophylact
studi
carri
merscov
mous
transgen
model
model
human
merscov
receptor
human
dipeptidyl
peptidas
express
carboxylesteras
delet
improv
pharmacokinet
nucleotid
prodrug
remdesivir
specif
coronaviru
demonstr
propag
viru
tissu
cultur
passag
presenc
drug
two
mutat
identifi
viral
rnadepend
rna
polymeras
gene
mutat
increas
replic
capac
viru
presenc
remdesivir
howev
amino
acid
chang
decreas
viral
fit
attenu
sarscov
pathogenesi
mice
efficaci
prophylact
therapeut
remdesivir
treatment
recent
test
nonhuman
primat
rhesu
macaqu
model
merscov
infect
prophylact
remdesivir
treatment
initi
h
prior
inocul
merscov
prevent
induc
clinic
diseas
inhibit
replic
respiratori
tissu
prevent
format
lung
lesion
similar
result
obtain
therapeut
remdesivir
treatment
initi
h
viru
inocul
human
safeti
data
avail
remdesivir
thu
human
trial
initi
test
efficaci
compound
novel
coronavirus
therapi
approv
food
drug
administr
fda
evalu
antivir
activ
sarscov
merscov
exampl
lopinavir
lpv
human
immunodefici
viru
proteas
inhibitor
combin
ritonavir
rtv
increas
lpv
halflif
combin
lpv
rtv
lpvrtv
shown
effect
sarscov
patient
tissu
cultur
estim
ec
fetal
rhesu
cell
gml
lpvrtv
also
reduc
weight
loss
clinic
score
viral
titer
diseas
progress
marmoset
infect
merscov
nevertheless
antivir
activ
lpv
merscov
tissu
cultur
remain
controversi
optim
ec
found
vero
cell
ec
report
cell
clinic
observ
anim
human
show
merscov
infect
mediat
viru
replic
host
inflammatori
respons
find
led
explor
combin
therapi
includ
type
interferon
ifni
ifnii
interferon
beta
display
best
efficaci
ec
iuml
reduc
merscov
replic
tissu
cultur
similarli
lpvrtv
clinic
improv
observ
common
marmoset
infect
merscov
kingdom
south
arabia
ongo
random
control
trial
miracl
trial
initi
determin
whether
combin
lpvrtv
could
improv
clinic
outcom
merscov
infect
importantli
anoth
control
trial
launch
china
test
efficaci
lpvrtv
hospit
patient
infect
clinicaltri
registr
prophylact
therapeut
properti
remdesivir
previous
compar
human
transgen
mous
merscov
infect
model
remdesivir
improv
pulmonari
function
reduc
lung
viral
load
amelior
sever
lung
patholog
contrast
prophylact
reduc
viral
load
slightli
impact
diseas
paramet
therapeut
improv
pulmonari
function
reduc
viru
replic
sever
lung
patholog
overal
result
indic
remdesivir
show
potenti
treat
merscov
infect
ribavirin
guanosin
analogu
antivir
compound
use
treat
sever
viru
infect
includ
respiratori
syncyti
viru
hepat
c
viru
viral
hemorrhag
fever
case
ribavirin
combin
ifn
ribavirin
first
market
treatment
respiratori
syncyti
viru
children
although
promis
result
obtain
previous
ribavirin
merscov
rhesu
macaqu
model
data
conflict
patient
merscov
infect
treat
combin
ribavirin
ifn
either
howev
ribavirin
reduc
hemoglobin
concentr
undesir
side
effect
patient
respiratori
disord
featur
reduc
potenti
antivir
work
influenza
viru
shown
monoclon
polyclon
antibodi
use
prophylact
therapeut
tool
sever
antibodi
shown
previous
bind
influenza
viru
hemagglutinin
inhibit
viru
replic
exampl
human
immunoglobulin
monoclon
antibodi
bind
highli
conserv
epitop
stalk
influenza
viru
hemagglutinin
phase
human
influenza
viru
challeng
studi
significantli
reduc
clinic
symptom
viral
burden
rel
placebo
anoth
exampl
monoclon
antibodi
engin
target
known
influenza
viru
strain
phase
trial
show
clinic
benefit
current
develop
effort
monoclon
polyclon
antibodi
coronavirus
mainli
target
merscov
phase
clinic
trial
human
polyclon
antibodi
gener
transchromosom
cattl
found
safe
well
toler
healthi
particip
howev
therapeut
treatment
human
monoclon
antibodi
protect
sever
diseas
loss
lung
function
induc
merscov
anim
model
lack
viral
sequenc
homolog
among
differ
human
coronavirus
suggest
current
investig
antibodybas
therapeut
effect
novel
viru
variant
nevertheless
consid
futur
treatment
novel
coronavirus
immunebas
therapi
discard
anoth
potenti
treatment
option
could
use
novel
coronaviru
sera
prepar
blood
patient
convalesc
convalescentphas
sera
passiv
immun
well
establish
viral
infect
prophylaxi
polyclon
antibodi
product
licens
target
cytomegaloviru
hepat
b
viru
varicellazost
viru
metaanalysi
report
influenza
viru
epidem
conclud
earli
administr
convalesc
blood
product
reduc
absolut
risk
pneumoniarel
death
nevertheless
appropri
titer
convalescentphas
sera
antibodi
requir
therapeut
efficaci
remain
determin
moreov
addit
studi
perform
influenza
viru
produc
controversi
result
regard
clinic
benefit
administ
high
titer
antiinfluenza
immunoglobulin
final
remain
unclear
whether
method
base
use
suffici
pool
potenti
donor
feasibl
work
carri
merscov
show
sera
patient
recov
infect
contain
suffici
antibodi
titer
therapeut
use
anoth
interest
therapeut
altern
previous
explor
influenza
viru
target
cellular
compon
involv
host
inflammatori
respons
infect
exampl
activ
inflammatori
respons
infect
induc
cytokin
outburst
result
acut
lung
injuri
exampl
therapi
type
infect
target
cellular
tolllik
receptor
specif
antibodi
transmembran
protein
belong
pattern
recognit
receptor
prr
famili
prototyp
pathogenassoci
molecular
pattern
pamp
recogn
correspond
gramneg
bacterium
endotoxin
lipopolysaccharid
lp
implic
patholog
associ
infect
tissu
damag
caus
noninfecti
insult
activ
lead
activ
nfb
intracellular
signal
pathway
inflammatori
cytokin
product
turn
activ
innat
immun
system
interestingli
mice
highli
resist
infect
mouseadapt
influenza
viru
thu
protect
influenza
viru
infect
achiev
target
smallmolecul
antagonist
like
antibodi
inde
target
cellular
protein
would
overcom
drawback
associ
viru
coronaviru
genet
heterogen
high
mortal
rate
observ
emerg
respiratori
diseas
induc
virus
like
merscov
sarscov
novel
influenza
viru
strain
given
rise
hypothesi
proinflammatori
respons
might
involv
diseas
pathogenesi
consequ
immunosuppress
eg
corticosteroid
might
use
adjunct
treat
sever
form
diseas
howev
therapeut
use
immunosuppress
free
controversi
date
conclus
result
found
effect
immunosuppress
sever
influenza
viru
infect
furthermor
use
corticosteroid
treat
influenza
viru
associ
increas
risk
superinfect
prolong
viral
replic
increas
risk
death
contrast
corticosteroid
treatment
merscov
infect
significantli
associ
mortal
although
delay
merscov
rna
clearanc
observ
studi
perform
clarifi
potenti
clinic
benefit
prescrib
immunosuppress
coronaviru
infect
end
minireview
discuss
interest
potenti
antivir
strategi
spike
protein
sarscov
mediat
viral
entri
target
cell
intriguingli
cleavag
activ
sarscov
spike
protein
host
cell
proteas
essenti
infecti
viral
entri
host
proteas
could
type
ii
transmembran
serin
proteas
shown
cleav
activ
sarscov
spike
protein
cell
cultur
therefor
potenti
target
antivir
intervent
exampl
serin
proteas
inhibitor
camostat
mesyl
inhibit
enzymat
activ
recent
administr
cystein
proteas
inhibitor
subnanomolar
rang
shown
inhibit
sarscov
merscov
replic
tissu
cultur
moreov
clinic
proven
serin
proteas
inhibitor
camostat
mesyl
activ
partial
block
spikedriven
entri
cell
futur
tissu
cultur
anim
model
studi
conduct
clarifi
potenti
antivir
activ
target
end
februari
month
first
case
report
china
sever
hundr
new
infect
case
regist
mainli
asian
region
europ
news
strongli
suggest
thick
pandem
social
alarm
health
author
call
develop
therapeut
altern
fight
current
possibl
new
coronaviru
epidem
anim
model
clinic
studi
urgent
need
evalu
effect
safeti
promis
antivir
compound
target
viru
andor
immunopatholog
involv
host
respons
identif
character
novel
compound
therapeut
altern
requir
better
control
probabl
pandem
outbreak
